Tue, Jul 22, 2014, 7:08 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • breezerwave breezerwave Dec 11, 2012 5:15 PM Flag

    7+% up so far for today

    Yes, with all the stupid shorters it was way oversold and now underpriced. Shorters advocating against a company that is trying to bring cancer treatments to market is bad karma. Certainly, they will change their tune some day when they have cancer or someone in their family does. Cometriq (cabo) will start to be sold and the pipeline of clinic trials with upcoming news and updates is great. See Exelixis website for all the triggers. Also take note of the following compound. Genentech in the past has had success after success with its cancer drug efforts.

    "About GDC-0973 (XL518)

    GDC-0973 is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase, also known as MEK, a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors. In preclinical studies, oral dosing of GDC-0973 resulted in potent and sustained inhibition of MEK in RAS or BRAF mutant tumor models. GDC-0973 is being developed by Genentech, a member of the Roche Group, under a collaboration agreement with Exelixis.

    Collaboration with Genentech
    Exelixis discovered GDC-0973 internally and advanced the compound to investigational new drug (IND) status. In late 2006, Exelixis entered into a worldwide co-development agreement with Genentech, under which Exelixis received initial upfront and milestone payments for signing the agreement and submitting the IND. Exelixis was responsible for development of GDC-0973 through the end of phase 1, at which point Genentech exercised its option to further develop the compound.

    Exelixis is entitled to an initial equal share of U.S. profits and losses, which will decrease as sales increase, and will share equally in the U.S. marketing and commercialization costs. Exelixis is eligible to receive royalties on any sales of the product outside the United States. Exelixis has the option to co-promote in the United States.


    As disclosed on ClinicalTrials.gov, a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial evaluating the combination of vemurafenib with GDC-0973 versus vemurafenib in previously untreated BRAFV600 mutation positive patients with unresectable locally advanced or metastatic melanoma was recruiting participants as of November 1, 2012."

    The above is from Exelixis website.

    Sentiment: Strong Buy

3.59+0.01(+0.28%)Jul 22 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.